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ldrin Lewis, MD, FACC
oston, Massachusetts
To travel hopefully is a better thing than to arrive.
—Robert Louis Stevenson (1)
he paper by Cleland et al. (2) for the Carvedilol or
etoprolol European Trial (COMET) investigators, in this
ssue of the Journal, portrays how the dynamic area of
atient well-being extends around the single dimension of
urvival time. Although the comparison of carvedilol and
etoprolol recapitulates the previously published results (3),
his article provides timely emphasis on incorporating how
atients feel. The challenge remains to understand how
ymptoms, quality of life, and the values placed on survival
ary on average for therapies and individually for patients.
he decisions to be made should determine how the
uestions will be asked.
See page 1603
Focus on the quality factor becomes increasingly critical
hen both quality and survival are imminently limited. The
lassic studies of heart failure therapies focused on patients
ith mild-moderate heart failure, for whom the demon-
trated benefits often have not detectably impacted quality
f life. Recently, in more advanced disease, biventricular
acing, left ventricular assist devices, and the nitrate-
ydralazine combination have substantially improved symp-
oms and function (4–6), using the same tools previously
hallenged as insensitive.
Assessment tools for heart failure can be disease specific,
elating to expected symptoms of heart failure, such as the
innesota Living with Heart Failure questionnaire and the
ansas City Cardiomyopathy Questionnaire (3,7) (Table 1).
hese may provide the most sensitive indicators of impact
or a heart failure intervention (8). In this study, the New
ork Heart Association (NYHA) symptom classification
as considered to be a disease-specific tool. Although it
ncludes patients’ description of symptoms, it is an assess-
ent made by the physician, subject to considerable inter-
retation and variation.
There are many generic instruments that describe general
imitations that can encompass non-cardiac side effects and
nderlying co-morbidities and allow extrapolation to other
isease states (8). Examples include the sickness impact
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.v
From the Brigham and Women’s Hospital, Cardiovascular Division, Boston,
assachusetts.rofile (SIP), short-form health survey (SF-36), and the
uroQOL. In this study, the primary tool used for serial
ssessment was the question “How have you been feeling
ver the past week?” with a five-point scale from very good
o very poor. This score with further validation could be a
eneric instrument.
The adjustment of actual survival time for perceived
ealth-related quality requires a conversion factor between 0
nd 1, with 1 being the best quality. This factor can be
onsidered a “utility” measure (9). Both disease-specific and
eneric quality-of-life instruments have intrinsic validity,
ut neither reveals the utility value placed on survival by the
atient. It has often been assumed that NYHA functional
lasses and patient assessments of how they feel can be
ranslated into a utility for modification of total survival
ime. A true utility, however, includes direct estimates of the
alue of survival time perceived by patients, determined
irectly by what duration of survival or chance of survival
hey would be willing to give up (9).
The two major utility tools are the time trade-off and the
tandard gamble, sometimes referred to as patient prefer-
nces (9). For the time trade-off utility, patients are taken
hrough sequential questions to determine how much time
hey would be willing to sacrifice in order to enjoy the
emaining time in perfect health. That preferred time is
ivided by the total time horizon offered to yield a fraction,
he utility, between 0 and 1. The fraction is progressively
ower as NYHA functional class is higher, but there is wide
ariability. There is a significant correlation with the Min-
esota scores but a weak one; many patients with the worst
cores still express a desire to live all remaining life without
ny trade-off (10). The other tool, the standard gamble, asks
he question of what risk of imminent death a patient would
ccept for the change to achieve perfect health. Results of
he standard gamble and time trade-off correlate more
losely with each other than either correlates with other
ssessments. However, unlike the time trade-off tool, the
tandard gamble includes the element of risk-seeking or
isk-aversion, and may also be influenced by the patient’s
revious outcomes from procedures. The EuroQOL
hermometer has been validated in terms of ranking
ifferent health states for pharmacoeconomic compari-
ons (8), but not when choices are to be made between
urvival and non-survival.
Assumption of utility is further complicated by the
istribution of responses, which is often bimodal, particu-
arly in heart failure. Most patients express either a willing-
ess to trade or risk almost all remaining time, or a
illingness to trade or risk almost no time for better health.
urthermore, when utility changes over time for an indi-
idual patient, it is usually by a large fraction, often reversing
he preference between survival and better health (11). This
hreshold effect challenges analyses, but in fact seems
ongruent when considering how most people describe the
alue they place on survival, and what would change it.
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April 18, 2006:1612–4 Editorial CommentIn the COMET study, many assumptions about the
atient journey were made to produce quality-adjusted
ife years. The five-point scale and the New York Heart
ssociation functional classes were used as ranks, which
ere then converted to utility values between 0 and 1,
ith the limitations as discussed above. Considerable care
as taken to repeat the analyses using several different
cales for this conversion, but each is limited by the two
ssumptions of a proportional relationship between ranks
nd utility values without accounting for the threshold
ffect, and a fixed relationship between symptoms and
tility among different patients. Well-being rank was
ecreased by one level if diuretic dose was increased,
lthough the increase might have been triggered (12) by
hanges in weight or physical examination before detect-
ble symptoms. For each interval of time covered, these
ank values were then multiplied by the days during that
nterval, which included those days for which the patient
as alive without hospitalization. Integration of actual patient
tilities with days alive out of hospital was a secondary end
oint, the “patient-preference adjusted survival,” pre-specified
or the Evaluation Study of Congestive Heart Failure and
ulmonary Artery Catheterization Effectiveness (ESCAPE)
rial (11,13).
Comparing therapies for a population in which most
atients survive with reasonable quality of life, the integral
f quality-adjusted survival did not differ from the primary
nd point for this trial or for the ESCAPE trial (3,12). For
he four years of the COMET study, the difference in total
djusted life lost was accounted for by the difference in
urvival as previously reported (3). The days lost to hospi-
alization were the same in both groups. The days lost to
mpaired quality as translated either by the five-point score
r the NYHA functional class were the same with carvedilol
nd metoprolol. Although not showing additional benefit,
he patient journey analysis does provide reassurance that
he added survival days for the carvedilol arm were not
iminished by worse quality than for metoprolol survivors.
The relevance of adjusted life-years depends on the
uestions being asked. The comparison of two therapies
able 1. Assessments of Symptoms, Quality, and Utility by Patie
Examples of Instruments for
Assessing Adult Health-
Related Quality of Life
Specific Heart Failure
Symptoms
innesota X
ansas City X
ew York Heart Association (Physician-classified)
isual analog: worst-best Can be constructed for
heart failure symptoms
Can be
“well-
hort-form 36
uroQOL
ickness Impact Profile
ime trade-off
tandard gambleith very similar clinical benefits and side effects is unlikely lo be enlightened by this integrated end point. In contrast,
patient-perceived utility measurement as a modifier of
ays alive may illuminate comparisons between two thera-
ies with disparate benefits and risks, such as might be used
n the future for ventricular assist devices (14) and home
notropic agents (15). Such comparisons would help to
uide choices of therapy for individual patients with differ-
nt survival preferences.
The use of the integrated adjusted life-year end point may
lso facilitate comparison of the cost-effectiveness of differ-
nt interventions tested in different populations. For in-
tance, the cost per quality-adjusted life year for carvedilol
ersus the short-acting metoprolol as used in this trial would
e approximately $40,000, based on local pharmacy costs.
his compares with an estimated $125 to $275 to save a
uality-adjusted life year by treating heart failure with
ngiotensin-converting enzyme inhibitors and metoprolol
n both developed and developing countries (16). Carvedilol
as not been compared with the other beta-blockers shown
o improve survival in heart failure, bisoprolol (17) or the
ong-acting metoprolol compound (18), for mortality or
ost effectiveness.
Beyond implications for trial design, sharpening focus on
he patient journey provides vital information on the im-
ortance that patients place on how well they live as well as
ow long they live. Over the course of this trial, approxi-
ately 25% of the total possible days were discounted for
mpaired quality. As heart failure becomes more advanced,
atients often voice a preference to trade half or more of
heir remaining time in order to feel better (10,11). Hearing
his message, can we afford to relegate health-related quality
f life to a secondary end point? For some journeys, the risk
f death may be more appropriately relegated to a “safety”
nd point, whereas the primary outcomes are those that
nable comfort, contribution, and companionship.
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